A Randomised Phase II trial investigating the duration of adjuvant therapy(6 versus 12 months) with S-1 for patients after resection of pancreatic cancer

Trial Profile

A Randomised Phase II trial investigating the duration of adjuvant therapy(6 versus 12 months) with S-1 for patients after resection of pancreatic cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PACS1
  • Most Recent Events

    • 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Apr 2016 Planned number of patients changed from 240 to 170, as reported by University Hospital Medical Information Network - Japan.
    • 06 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top